ClinicalTrials.gg
CompletedNCT03573271Updated Apr 9, 2026

Pivotal Study to Evaluate the Safety and Efficacy of a Micro-coring Device Treating Moderate to Severe Facial Wrinkles

An interventional study of MCD in Laxity; Skin, sponsored by Cytrellis Biosystems, Inc.. Completed at 5 sites in United States. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Cytrellis Biosystems, Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 8 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
40 Years to 70 Years
Sex
All
01

Study summary

Study evaluating the safety and efficacy of a micro-coring device for the treatment of moderate to severe cheek wrinkles.

Read the detailed description

Up to 60 subjects who meet the Inclusion/Exclusion criteria will be treated. All subjects will be monitored for a period of 90 days after treatments.

Evaluation results will be based in the following:

  • Wrinkle severity score assessed using the Lemperle Wrinkle Scale
  • Subject Satisfaction Scale
  • PI Global Aesthetic Improvement Scale
02

Conditions studied

  • Laxity; Skin

Keywords

  • facial wrinkles
  • skin laxity
  • sagging skin
03

In context

Lead sponsor

Cytrellis Biosystems, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 40-70 years of age
  • Fitzpatrick Skin Type I to IV as judged by the Investigator.
  • Cheek areas are at least a score of 3 using the Lemperle Wrinkle Assessment Scale as judged by the Investigator
  • Able to provide written , understand and willing to comply with all study related procedures and follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Lesions suspicious for any or the presence of actinic keratosis, melasma, vitiligo, cutaneous papules/nodules or active inflammatory lesions in the areas to be treated
  • History of keloid formation or hypertrophic scarring
  • History of trauma or surgery to the treatment areas in the past 6 months
  • Scar present in the areas to be treated
  • Silicone injections in the areas to be treated
  • Injection of dermal fillers, fat or botulinum toxin, as well as any minimally invasive/invasive medical device for skin treatment, in the study treatment areas, within the past 6 months (i.e., dermabrasion, laser, RF devices)
  • Active smokers (0.5 pack/day) or having quit within 3 months prior to treatment
  • Active, chronic, or recurrent infection
  • History of compromised immune system or currently being treated with agents
  • History of sensitivity to analgesic agents, Aquaphor®, topical or local anesthetics (e.g., lidocaine, benzocaine, procaine) or chlorhexidine, povidone-iodine or epinephrine
  • Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment
  • Treatment with aspirin or other blood thinning agents within 14 days prior to treatment
  • History or presence of any bleeding disorder
  • Any issue that, at the discretion of the Investigator, would interfere with assessment of safety or efficacy or compromise the subject's ability to participate in the study
  • Treatment with an device or agent within 30 days before treatment or during the study period
  • Female and pregnant or plan on becoming pregnant during the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Micro-coring of facial/neck skin with MCD

    Micro coring of facial and neck skin will be conducted in up to 2 treatments and followed 90 days post treatment with MCD

    Device: MCD

Interventions

  • DeviceMCD

    Micro-coring skin removal with automated coring device

06

What researchers measure

Primary outcomes

  1. Assess level of wrinkle improvement using the Lemperle Wrinkle Severity Scale at 90 days post treatment

    Assess level of wrinkle improvement from the baseline to 90 day post treatment an Independent Reviewer(s) using the Lemperle Wrinkle Severity Scale

    Time frame: 90 day post treatment

Secondary outcomes

  1. Assess safety profile by recording of adverse events

    Adverse events will be recorded throughout the study

    Time frame: 90 days

07

Study locations

5 sites
  • Laser and Skin Surgery Center of Northern California
    Sacramento, California 95816, United States
  • Miami Dermatology and Laser Institute
    Miami, Florida 33173, United States
  • Laser and Skin Surgery Center of New York
    New York, New York 10016, United States
  • The Practice of Brian S. Biesman, M.D
    Nashville, Tennessee 37203, United States
  • Dr A Jay Burns Cosmetic Surgery
    Dallas, Texas 75231, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Feb 2019, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2018
First posted
Jun 29, 2018
StartActual
Mar 26, 2018
Primary completionActual
Feb 28, 2019
CompletionActual
Feb 28, 2019
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03573271
Lead sponsor
Cytrellis Biosystems, Inc.
Responsible party
Sponsor
First posted
Jun 29, 2018
Start date
Mar 26, 2018
Primary completion
Feb 28, 2019
Completion
Feb 28, 2019
Last update
Apr 9, 2026

Study contacts

Patricia Krantz
study director · Cytrellis Biosystems, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion